A Study to Assess the Tolerability, Safety, and Pharmacokinetics of Subcutaneous Immune Globulin Infusion 10% (Human) With Recombinant Human Hyaluronidase (HYQVIA/HyQvia) With Ramp-up and No Ramp-up Dosing in Healthy Adult Participants

NCT04578535 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

51

Enrollment

INDUSTRY

Sponsor class

Conditions

Healthy Volunteers

Interventions

DRUG: HYQVIA
DRUG: HYQVIA
DRUG: HYQVIA
DRUG: HYQVIA
DRUG: HYQVIA
DRUG: HYQVIA

Sponsor

Baxalta now part of Shire

Collaborators

[object Object]